TY - JOUR
T1 - Prevention of transplant coronary artery disease by prenylation inhibitors
AU - Stein, William
AU - Schrepfer, Sonja
AU - Itoh, Satoshi
AU - Kimura, Naoyuki
AU - Velotta, Jeffrey
AU - Palmer, Owen
AU - Bartos, Jason
AU - Wang, Xi
AU - Robbins, Robert C.
AU - Fischbein, Michael P.
N1 - Funding Information:
This work was supported by the Falk Research Fund, Department of Cardiothoracic Surgery at Stanford University Medical School, American Association for Thoracic Surgery (Norman E. Shumway Award to M.P.F.) and an NRSA postdoctoral fellowship (to W.S.).
PY - 2011/7
Y1 - 2011/7
N2 - Background: In this study we systematically dissect the prenylation pathway to better define the mechanism behind statin inhibition in chronic allograft rejection in heart transplants, or transplant coronary artery disease (TCAD). Methods: Utilizing a murine heterotopic heart transplant model, animals received daily treatments of either statin or selective isoprenoid blockade inhibitors to block the four major downstream branches of the mevalonate pathway. TCAD was assessed by morphometric analysis at Day 52. Graft-infiltrating cells, cytokine production, smooth muscle cell proliferation and migration and endothelial cell MHC II expression were detected on Day 7. Results: Atorvastatin and two prenylation inhibitors, NE-10790 and manumycin A, significantly reduced TCAD lesions compared with untreated animals. Perillyl alcohol treatment resulted in a trend toward decreased luminal narrowing. Finally, zaragozic acid (cholesterol blockade only) did not alter TCAD severity. Statins and prenylation inhibitors reduced inflammatory cell allograft recruitment, but did not always correlate with TCAD reduction. Cytokine production was decreased in recipient spleens in all treatment groups. Both in vitro and in vivo IFN-γstimulated MHC II expression was decreased in a dose-dependent manner in the atorvastatin, perillyl alcohol and NE-10790 groups. In vitro smooth muscle cell proliferation was decreased in all treatment groups. Finally, in vitro smooth muscle cell migration was decreased in the atorvastatin, NE-10790 and manumycin A groups only. Conclusions: FPT and GGPT-2 (inhibition) are the key enzymes in the HGM-CoA reductase pathway and most influential in TCAD prevention. TCAD reduction is most closely related to smooth muscle cell migration, but not its anti-inflammatory properties.
AB - Background: In this study we systematically dissect the prenylation pathway to better define the mechanism behind statin inhibition in chronic allograft rejection in heart transplants, or transplant coronary artery disease (TCAD). Methods: Utilizing a murine heterotopic heart transplant model, animals received daily treatments of either statin or selective isoprenoid blockade inhibitors to block the four major downstream branches of the mevalonate pathway. TCAD was assessed by morphometric analysis at Day 52. Graft-infiltrating cells, cytokine production, smooth muscle cell proliferation and migration and endothelial cell MHC II expression were detected on Day 7. Results: Atorvastatin and two prenylation inhibitors, NE-10790 and manumycin A, significantly reduced TCAD lesions compared with untreated animals. Perillyl alcohol treatment resulted in a trend toward decreased luminal narrowing. Finally, zaragozic acid (cholesterol blockade only) did not alter TCAD severity. Statins and prenylation inhibitors reduced inflammatory cell allograft recruitment, but did not always correlate with TCAD reduction. Cytokine production was decreased in recipient spleens in all treatment groups. Both in vitro and in vivo IFN-γstimulated MHC II expression was decreased in a dose-dependent manner in the atorvastatin, perillyl alcohol and NE-10790 groups. In vitro smooth muscle cell proliferation was decreased in all treatment groups. Finally, in vitro smooth muscle cell migration was decreased in the atorvastatin, NE-10790 and manumycin A groups only. Conclusions: FPT and GGPT-2 (inhibition) are the key enzymes in the HGM-CoA reductase pathway and most influential in TCAD prevention. TCAD reduction is most closely related to smooth muscle cell migration, but not its anti-inflammatory properties.
KW - chronic rejection
KW - heart transplantation
KW - prenylation inhibition
KW - smooth muscle cells
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=79959203476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959203476&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2011.01.720
DO - 10.1016/j.healun.2011.01.720
M3 - Article
C2 - 21458297
AN - SCOPUS:79959203476
SN - 1053-2498
VL - 30
SP - 761
EP - 769
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 7
ER -